GlassScriptPhysician profile
Elisa Thompson
NPI 1467791848
$9,379.95
in general payments reported to CMS, 2019-2025
27 companies · $2,647 in 2025
The $2,647 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $309 · 2022: $1,687 · 2023: $2,812 · 2024: $1,926 · 2025: $2,647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,379 · Consulting Fee: $875 · Education: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,379.28 |
| Consulting Fee | $875.00 |
| Education | $129.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,540.52 | 2022-2025 | Fasenra, Tezspire, Airsupra |
| Genentech USA, INC. | $1,223.51 | 2022-2025 | Xolair |
| Regeneron Healthcare Solutions, INC. | $792.68 | 2022-2025 | Dupixent |
| Amgen INC. | $675.47 | 2022-2025 | Tezspire |
| Glaxosmithkline, LLC. | $674.26 | 2021-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Genentech, INC. | $535.48 | 2023-2025 | Xolair |
| Genzyme Corporation | $508.89 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $441.14 | 2022-2025 | |
| Csl Behring | $353.40 | 2022-2025 | Hizentra, Haegarda, Andembry |
| Grifols USA, LLC | $323.86 | 2022-2025 | Prolastin-C Liquid, Xembify |
| Optinose US, INC. | $248.24 | 2022-2025 | |
| Ars Pharmaceuticals Operations, INC. | $196.84 | 2025 | Neffy |
| Takeda Pharmaceuticals U.S.A., INC. | $174.51 | 2022-2025 | Cuvitru, Hyqvia |
| Regeneron Pharmaceuticals, INC. | $142.05 | 2024 | Dupixent |
| Blueprint Medicines Corporation | $95.65 | 2023 | Ayvakit |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $79.35 | 2023 | Ryaltris |
| Sanofi-Aventis U.S. LLC | $72.00 | 2025 | |
| Aimmune Therapeutics, INC. | $62.46 | 2022 | |
| Abbvie INC. | $46.35 | 2022 | |
| Teleflex LLC | $34.26 | 2025 | Arrow |
| Galderma Laboratories, L.P. | $29.74 | 2025 | Nemluvio |
| Pharming Healthcare, INC. | $29.34 | 2025 | Ruconest |
| Pfizer INC. | $29.03 | 2025 | |
| Leo Pharma INC. | $19.21 | 2023 | Adbry |
| Kaleo, INC. | $18.17 | 2022 | |
| Alk-Abello, INC | $17.76 | 2023 | Ragwitek, Odactra, Grastek |
| Biocryst US Sales Co., LLC | $15.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elisa Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.